| Market Capitalization (Millions $) |
1,017 |
| Shares
Outstanding (Millions) |
139 |
| Employees |
288 |
| Revenues (TTM) (Millions $) |
108 |
| Net Income (TTM) (Millions $) |
-97 |
| Cash Flow (TTM) (Millions $) |
102 |
| Capital Exp. (TTM) (Millions $) |
1 |
Wave Life Sciences Ltd
Wave Life Sciences Ltd is a clinical-stage genetic medicine company that was founded in 2012 and is headquartered in Singapore. The company is dedicated to developing RNA-targeted therapies for the treatment of rare genetic diseases and has two primary product platforms e stereopure oligonucleotides and allele-selective therapeutic candidates.
The stereopure oligonucleotide platform focuses on the creation of oligonucleotide-based therapeutics that are designed to selectively target and modulate the expression of specific disease-causing genes. These therapeutics are engineered using proprietary synthetic chemistry and manufacturing processes that eliminate impurities and maximize potency and precision.
The allele-selective therapeutic platform is designed to develop targeted therapies that specifically address genetic mutations associated with hereditary disorders. These therapies are designed to selectively target the mutant form of a gene while leaving the healthy, wild-type gene intact.
Wave has a broad pipeline of investigational therapies across neurology, ophthalmology, dermatology, cardiology, and other therapeutic areas. The company has a number of clinical programs underway, including in Huntington's disease, DMD, and acute myeloid leukemia, as well as early-stage programs in other genetic diseases such as Duchenne muscular dystrophy, ALS, and Friedreich's ataxia.
In addition to its research and development efforts, Wave is also focused on building strategic partnerships with other leading biotech and pharmaceutical companies to co-develop and commercialize its therapies. The company has established partnerships with several key industry players, including Takeda, Pfizer, and Vertex Pharmaceuticals.
Overall, Wave Life Sciences Ltd is a pioneer in the field of RNA-targeted therapies, with a broad range of innovative therapeutics under development that have the potential to transform the lives of patients with rare genetic diseases. The company is well-positioned for future growth and success in this rapidly evolving field.
Company Address: 7 Straits View #12-00 East Tower 18936
Company Phone Number: 6236 3388 Stock Exchange / Ticker: NASDAQ WVE
|
6.29% 